After a stellar October, the equities market and stock exchange traded funds had a more tepid November, with traders waiting for a potential rate hike in December.
Over November, the Dow Jones Industrial Average was down 0.6%, the Nasdaq Composite was 0.4% lower and the S&P 500 dipped 1.1%.
The best performing non-leveraged ETFs over the past month include KraneShares CSI New China ETF (NYSEArca: KFYP) up 14.7%, BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC) up 13.0% and Deutsche X-trackers Japan JPX-Nikkei 400 Hedged Equity ETF (NYSEArca: JPNH) up 12.0%.
Despite a brief stumble toward the end of the month, China’s market have been in full bull-market-rally mode, with the Shanghai Composite Index rallying over 20% since its August lows. [China ETFs’ Worst Stumble Since August]
The continued merger and acquisition activity helped support the healthcare and biotech industries. Biotechnology sector-specific ETFs that track smaller companies were outperforming as these funds track small, specialized drug makers that could potentially be acquisition targets down the line. [Biotech ETFs Start Week With A Surge]
Currency-hedged Japan ETFs have been a popular way to capture favorable growth opportunities in the developed Asia Pacific economy as monetary and fiscal policies help support the country’s outlook. [Central Banks Complicate Capturing Japan ETF Returns]
The worst performing non-leveraged exchange traded products over the past month include the ETFS Physical Palladium Shares (NYSEArca: PALL) down 19.1%, Global X Copper Miners ETF (NYSEArca: COPX) down 18.9% and E-TRACS UBS Long Platinum ETN (NYSEArca: PTM) down 18.4.